History and innovation: Cytotoxic chemotherapy for breast cancer (notice n° 177323)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01492cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040633.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Diéras, Véronique |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | History and innovation: Cytotoxic chemotherapy for breast cancer |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 83 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Breast cancer is considered a systemic disease requiring medical treatment, as surgery is unable to prevent the occurrence of metastasis. Moreover, biological arguments support early treatment to prevent metastasis . Neoadjuvant cytotoxic chemotherapy was initially proposed for non-operable locally advanced breast cancer, and then for operable breast cancer not suitable for breast-conserving surgery, in order to decrease the number of mastectomies. The concept was validated in the NASBP-B18 trial and confirmed by numerous studies. A complete pathological response was associated with better prognosis, allowing this criterion to be used as a surrogate marker for efficacy. In addition, incomplete responses have enabled those at high risk of relapse to be identified and new options to be proposed. Neoadjuvant treatment is currently included in all guidelines. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Du, Fanny |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pierga, Jean-Yves |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 10 | 2 | 2024-04-17 | p. 111-116 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-2-page-111?lang=en">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-2-page-111?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux